PDS Biotechnology (PDSB) Q1 2026 earnings summary

Executive summary

• Amended the VERSATILE-003 Phase 3 trial to use progression-free survival as an interim primary endpoint, aiming for accelerated approval and reduced trial duration and costs, with FDA alignment and maintained site momentum.

• Completed enrollment in the metastatic colorectal cancer trial for PDS01ADC and continued strong recruitment in the advanced castration-resistant prostate cancer trial, with published positive clinical and biomarker data.

• Strengthened intellectual property for PDS0101 with new patents in the U.S. and Japan, extending market protection into the 2040s.

• No commercial products or revenues; operations funded through equity and debt financings.

• Pipeline includes Versamune and PDS01ADC platforms, with multiple ongoing and completed clinical trials in HPV-related cancers and other indications.

Financial highlights

• Net loss for Q1 2026 was $7.3 million ($0.13 per share), improved from $8.5 million ($0.21 per share) in Q1 2025.

• Research and development expenses decreased to $3.5 million from $5.8 million year-over-year, mainly due to lower clinical and manufacturing costs.

• General and administrative expenses were $3.1 million, down from $3.3 million year-over-year.

• Cash and cash equivalents as of March 31, 2026, were $21.7 million.

• No income tax benefit in Q1 2026 due to reaching the statutory cap on NOL sales; $1.2 million benefit was recognized in Q1 2025.

Outlook and guidance

• Anticipates additional data from the fully enrolled colorectal cancer cohort by year-end.

• Manufacturing processes for Versamune are established, with remaining activities focused on validation batches for BLA filing.

• Company expects continued operating losses and negative cash flows for the foreseeable future, with substantial doubt about the ability to continue as a going concern.

• Plans to seek additional capital through equity, debt, or strategic partnerships.

• Ongoing focus on advancing PDS0101 and PDS01ADC as key components of the immuno-oncology pipeline.